EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.


Cornberg M(1), Buti M(2), Eberhardt CS(3), Grossi PA(4), Shouval D(5).
Author information:
(1)Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; Centre for Individualised Infection Medicine
(CiiM), a joint venture of Helmholtz Centre for Infection Research and Hannover Medical School, Hannover, Germany; German Center for Infection Research
(DZIF), Partner-Site Hannover-Braunschweig, Hannover, Germany. Electronic address: [Email]
(2)Liver Unit. Hospital Universitario Valle Hebron and Ciber-ehd del Instituto Carlos III, Barcelona, Spain.
(3)Center for Vaccinology, University Hospitals of Geneva and Faculty of Medicine, University of Geneva, Switzerland and Emory Vaccine Center, Emory University, Atlanta, GA, USA.
(4)Infectious and Tropical Diseases Unit, Department of Medicine and Surgery University of Insubria and ASST-Sette Laghi, Varese, Italy; Italian National Center for Transplantation, Rome, Italy.
(5)Liver Unit, Department of Medicine, Hadassah-Hebrew University Hospital, Jerusalem, Israel.


Comment in J Hepatol. 2021 Aug;75(2):483-484.